A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer

New insights into IL-12-mediated tumor suppression

(2014) S Tugues et al.   CELL DEATH AND DIFFERENTIATION

Chemotherapy Alters Monocyte Differentiation to Favor Generation of Cancer-Supporting M2 Macrophages in the Tumor Microenvironment

(2013) E. M. Dijkgraaf et al.   CANCER RESEARCH

The Immune System in the Pathogenesis of Ovarian Cancer

(2013) Bridget Charbonneau et al.   CRITICAL REVIEWS IN IMMUNOLOGY

Interleukin-6 Receptor Blockade Selectively Reduces IL-21 Production by CD4 T Cells and IgG4 Autoantibodies in Rheumatoid Arthritis

(2013) Gustavo Carbone et al.   International Journal of Biological Sciences

Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: Correlation of CD163 expression, cytokine levels and early relapse

(2013) Silke Reinartz et al.   INTERNATIONAL JOURNAL OF CANCER

Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer

(2013) Vincent Lavoué et al.   Journal of Translational Medicine

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Ratios of CD8+ T Cells to CD4+CD25+ FOXP3+ and FOXP3- T Cells Correlate with Poor Clinical Outcome in Human Serous Ovarian Cancer

(2013) Claudia C. Preston et al.   PLoS One

Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus

(2012) Yuko Shirota et al.   ANNALS OF THE RHEUMATIC DISEASES

Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: A phase I/II clinical trial

(2012) Eliane C.M. Zeestraten et al.   INTERNATIONAL JOURNAL OF CANCER

In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment

(2011) Petra Roll et al.   ARTHRITIS AND RHEUMATISM

Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer

(2011) Jermaine Coward et al.   CLINICAL CANCER RESEARCH

Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)

(2011) Gordon John Sampson Rustin et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes

(2011) M. Gooden et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study

(2010) Gabor G. Illei et al.   ARTHRITIS AND RHEUMATISM

Immunological and Inflammatory Functions of the Interleukin-1 Family

(2009) Charles A. Dinarello   Annual Review of Immunology

“MIATA”—Minimal Information about T Cell Assays

(2009) Sylvia Janetzki et al.   IMMUNITY

Granulocyte colony stimulating factor in HCV genotype-1 patients who develop Peg-IFN-α2b related severe neutropenia: A preliminary report on treatment, safety and efficacy

(2009) John Koskinas et al.   JOURNAL OF MEDICAL VIROLOGY

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

(2008) N. Nishimoto et al.   BLOOD

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET